We are live on ! Find out more
ARTV icon

Artiva Biotherapeutics

48 hedge funds and large institutions have $27.9M invested in Artiva Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 53 → 48 (-5)

9.91% less ownership

Funds ownership: 85.88% → 75.97% (-9.9%)

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

44% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 16

77% less capital inflows, than outflows

Capital inflows: $1.82M | Capital outflows: $8M

Holders
48
Holders Change
-5
Holders Change %
-9.43%
% of All Funds
0.63%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
12
Increased
9
Reduced
16
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ARTV Hedge Fund Activity: Q2 2025 in Review

48 of the 7,634 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q2 2025, worth a combined $27.9M — down 55% from $62.8M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of ARTV and 12 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 9 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $687K. The largest seller was Capital World Investors, exiting entirely with an estimated $2.6M sold.

  • 48 institutional investors held Artiva Biotherapeutics (ARTV) as of Q2 2025, down from 53 in Q1 2025.
  • Funds reported $27.9M of Artiva Biotherapeutics stock for Q2 2025, down 55% quarter-over-quarter.
  • 12 funds opened new Artiva Biotherapeutics positions in Q2 2025 and 17 closed out, a net change of -5 holders.
  • The largest Artiva Biotherapeutics buyer in Q2 2025 was Millennium Management, an estimated $687K added.
  • The largest Artiva Biotherapeutics seller in Q2 2025 was Capital World Investors, an estimated $2.6M sold.

Based on aggregated 13F filings for Q2 2025.